Why is Quest Diagnostics stock sliding today?
Quest Diagnostics (DGX) stock fell 5.2% in after-hours trading to $232.12 after CMS proposed cuts to lab reimbursement rates, potentially reducing payments by 15% starting 2027. The announcement follows DGX's 52-week high of $248.84. Truist Securities maintained a Hold rating but raised its price target to $260. Competitor Labcorp (LH) was also affected, indicating a sector-wide impact.
How this was made
The 30-second read
Why it matters
The announcement creates immediate downside risk for Quest Diagnostics and peers, with a 5.2% after‑hours decline.
Market read
Regulatory news directly impacts revenue expectations for DGX and the broader lab services sector.
What to watch
Potential for industry lobbying and comment period may delay implementation, reducing near‑term impact.
Background
CMS released preliminary reimbursement proposals affecting Medicare lab fee payments.
Ticker impact
CMS proposed reimbursement cuts could reduce Quest Diagnostics' lab fee payments by up to 15%, driving a 5.2% after‑hours price drop.
Further downside pressure if final rates are confirmed; potential rebound if comments mitigate cuts.
The cut directly hits the core revenue stream and the move already caused a 5% sell‑off.
Market effects
Other clinical laboratory companies face similar reimbursement risk, potentially weighing on the sector.
U.S. healthcare services segment may see modest pressure.
Limited to U.S. lab services; no immediate global ripple.
Counterpoint
If CMS finalizes rates with less severe cuts, DGX could rebound sharply, offering a buying opportunity.
Key entities
- companyQuest Diagnostics
U.S. clinical laboratory services provider (ticker DGX).
- regulatorCenters for Medicare & Medicaid Services
U.S. federal agency proposing the reimbursement changes.
